Stryker Co. (NYSE:SYK) Shares Bought by Level Four Advisory Services LLC

Level Four Advisory Services LLC increased its holdings in shares of Stryker Co. (NYSE:SYK) by 31.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,204 shares of the medical technology company’s stock after purchasing an additional 285 shares during the quarter. Level Four Advisory Services LLC’s holdings in Stryker were worth $361,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SYK. Magellan Asset Management Ltd boosted its stake in Stryker by 74,911.8% during the third quarter. Magellan Asset Management Ltd now owns 680,357 shares of the medical technology company’s stock valued at $185,921,000 after buying an additional 679,450 shares in the last quarter. Barclays PLC boosted its stake in Stryker by 103.5% during the third quarter. Barclays PLC now owns 1,084,987 shares of the medical technology company’s stock valued at $296,493,000 after buying an additional 551,798 shares in the last quarter. Morgan Stanley boosted its position in shares of Stryker by 4.4% in the 3rd quarter. Morgan Stanley now owns 5,315,227 shares of the medical technology company’s stock valued at $1,452,493,000 after purchasing an additional 223,728 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Stryker by 24.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,115,955 shares of the medical technology company’s stock valued at $304,957,000 after purchasing an additional 217,672 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in Stryker by 14.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,547,683 shares of the medical technology company’s stock worth $422,099,000 after acquiring an additional 194,715 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Barclays raised their price objective on Stryker from $372.00 to $376.00 and gave the stock an “overweight” rating in a research report on Thursday, May 2nd. Wells Fargo & Company raised their price target on Stryker from $364.00 to $381.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. TD Cowen raised their price target on Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. BTIG Research raised their price target on Stryker from $366.00 to $369.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Finally, Truist Financial raised their price objective on Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a research note on Wednesday, January 31st. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $367.32.

Stryker Trading Up 1.5 %

SYK stock opened at $335.42 on Thursday. The company has a market cap of $127.78 billion, a P/E ratio of 38.29, a PEG ratio of 2.60 and a beta of 0.91. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $361.41. The company has a quick ratio of 0.99, a current ratio of 1.71 and a debt-to-equity ratio of 0.56. The business has a fifty day moving average of $340.69 and a 200-day moving average of $323.38.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.36 by $0.14. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The firm had revenue of $5.24 billion during the quarter, compared to analysts’ expectations of $5.10 billion. During the same period in the previous year, the firm earned $2.14 earnings per share. The company’s revenue was up 9.7% on a year-over-year basis. As a group, equities research analysts expect that Stryker Co. will post 11.95 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Friday, June 28th will be given a dividend of $0.80 per share. The ex-dividend date is Friday, June 28th. This represents a $3.20 annualized dividend and a yield of 0.95%. Stryker’s dividend payout ratio (DPR) is presently 36.53%.

Insider Buying and Selling at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the sale, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.